TickerFacts.

Denali Therapeutics Inc. (DNLI): Shareholders' Equity

Annual figures by period end, from SEC filings.

$1.01B
As of 2025-12-31
$835.18M
As of 2026-06-30
-0.9%
3-year compound annual growth
-2.5%
5-year compound annual growth
$1.23B2016-12-31: -$94.15M2017-12-31: $465.80M2018-12-31: $546.85M2019-12-31: $394.89M2020-12-31: $1.15B2021-12-31: $962.29M2022-12-31: $1.04B2023-12-31: $1.03B2024-12-31: $1.23B2025-12-31: $1.01B$1.01B
2016-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$1.01B-17.6%2026-02-26, Balance as of period end
2024-12-31$1.23B+19.3%2026-02-26, Balance as of period end
2023-12-31$1.03B-1.1%2026-02-26, Balance as of period end
2022-12-31$1.04B+8.3%2025-02-27, Balance as of period end
2021-12-31$962.29M-16.4%2024-02-28, Balance as of period end
2020-12-31$1.15B+191.4%2023-02-27, Balance as of period end
2019-12-31$394.89M-27.8%2022-02-28, Balance as of period end
2018-12-31$546.85M+17.4%2021-02-26, Balance as of period end
2017-12-31$465.80Mn/m2020-02-27, Balance as of period end
2016-12-31-$94.15Mn/a2019-03-12, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Denali Therapeutics Inc. (DNLI)2025-12-31$1.01B-17.6%
Vaxart, Inc. (VXRT)2025-12-31$87.80M+49.0%
Amgen Inc (AMGN)2025-12-31$8.66B+47.3%
Repligen Corp (RGEN)2025-12-31$2.11B+6.8%
Champions Oncology, Inc. (CSBR)2026-04-30$3.94M+4.4%
Bio-Techne Corp (TECH)2026-06-30$2.11B+9.9%
Biogen Inc. (BIIB)2025-12-31$18.26B+9.2%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$43.35M-43.7%
Gilead Sciences, Inc. (GILD)2025-12-31$22.62B+17.5%

Compare DNLI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗